VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.
TIMI 11BESSENCE Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis Antman EM et al, Circulation 1999 Oct 12;100(15):
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Improved Care for Acute Myocardial Infarction Linking Referral and Receiving Centres – How can We Communicate Better? Dr. James McMeekin AMI Faculty Cardiologist,
TACTICS-TIMI 18 Economics & HRQOL Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Impella Technology Elective Support Clinical Evidence and Investigations.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Treatment strategies for “stable” CAD patients: COURAGE, OAT, SWISSI II, VIAMI in perspective Pierfrancesco Agostoni, MD Antwerp Cardiovascular Institute.
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
MICHELANGELO: OASIS 5 Women’s Substudy Dr. Eva Swahn Department of Cardiology, Heart Centre, University Hospital, Linköping Sweden Disclosure Funded by.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
The Benefit of an Invasive Strategy in Women Versus Men with Non-ST-Elevation ACS: A Collaborative Meta-Analysis of Randomized Trials Michelle O’Donoghue,
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
AntiThrombotic Therapy in the Cath Lab: Preliminary Results from the NICE Trials Cindy L. Grines, M.D. William Beaumont Hospital Royal Oak, Michigan Cindy.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Prognosis of Patients With LV Dysfunction and CAD
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
European Heart Association Journal 2007 April
Section 5: Intervention and drug therapy
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Invasive versus conservative treatment in unstable coronary syndromes
Published in the European Heart Journal
Randomized Comparison in the Setting of Acute MI
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
The European Society of Cardiology Presented by RJ De Winter
American College of Cardiology Presented by Dr. Michel R. Le May
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
LRC-CPPT and MRFIT Content Points:
Maintenance of Long-Term Clinical Benefit with
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Atlantic Cardiovascular Patient Outcomes Research Team
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Presentation transcript:

VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial

VA NQWISH l Compare outcomes of patients with non-Q wave MI, managed with an early invasive stategy vs. an early conservative strategy Goal

VA NQWISH Inclusion / Exclusion l Inclusion Criteria: Clinical presentation consistent with acute MI Clinical presentation consistent with acute MI CK-MB > 1.5 times upper limit of normal CK-MB > 1.5 times upper limit of normal No Q wave on ECG (could be ST elev without Q waves) No Q wave on ECG (could be ST elev without Q waves) Onset within 72 hours of randomization Onset within 72 hours of randomization l Exclusion Criteria: s High risk (ongong ischemia, CHF, arrhythmias) s Recent revascularization

VA NQWISH Treatment Strategies l Invasive: s Cardiac catheterization within 3-7 days s Revascularization if possible s (PTCA for 1 or 2VD, CABG for 3VD) l Conservative: s Mecical management s RVG s ETT / Thallium pre-discharge s Cath if ETT + or recurrent ischemia at rest with ECG changes

VA NQWISH Statistics l Equivalence Design: l i.e, No difference in clinical outcome between the two strategies l Primary End Point: Death or non-fatal MI through follow-up (minimum 1 year) l Assumed 20% event rate in each arm. l 85% power, p=0.05

VA NQWISH Patient Flow 17 VA Hosptial Across U.S.

VA NQWISH Catheterization / Revascularization No. Pts Cath (%) < H Disch < H Disch >H Disch >H Disch Revasc. (%) Time to revasc (mean, days) Invasive Invasive Conservative

VA NQWISH Outcomes No. Pts Death/MI to F/U (%) Death (%) Non-fatal MI (%) Death < H Disch Death >H Disch L.O.S. (days) Invasive Invasive Conservative NS0.007NS<0.001 P value P value

VA NQWISH Conservative vs. Invasive Death/MIMortality ( ) ( ) Hazard Ratios Hazard Ratio 95% Conf. Interval

VA NQWISH F In-hosptial deaths: 21 Invasive vs. 6 Conservative F 11 of 21 deaths were post CABG (13.4% perioperative mortality) F 0 deaths post PTCA F Recent Ontario study CABG patients : F Total perioperative mortality 3.14% F Patients with recent MI = mortality 12.6% Peri-Procedural Complications

VA NQWISH F Patients with non-Q wave MI in this trial did not benefit from early invasive strategy and may be harmed. F A conservative, “ischemia-guided” management approach is both safe and effective Conclusions

Observations from TIMI IIIB and VANQWISH F An invasive strategy did not prevent recurrent MI F Outcome of invasive strategy depends on peri- procedural complication rate, influenced by: n Procedure (PTCA vs. CABG) n Hospital n Patient population

100$2,353,671 No. Pts Total Costs Invasive100$2,184,092 Conservative Conservative Cost Analysis - Invasive vs. Conservative (using TIMI IIIB as a model) Conti CR. Clin Cardiol 1995;18: Invasive strategy $1696 per patient added cost (1.5% lower rate of death or MI by 1 year)